Gene Therapy for CD19-Positive Blood Cancers (SENTRY-CD19)
This study is testing a new gene therapy called VNX-101 for people with certain types of B-cell leukemia and lymphoma that have come back or are not responding to treatment. VNX-101 is designed to help your body's immune cells (T-cells) find and kill cancer cells that have a specific marker called CD19. The study will look at how safe VNX-101 is and how well it works. To join, you must be between 13 and 90 years old, have CD19-positive cancer, and meet other health requirements. The main goal is to track any side effects over five years. The current recruitment status is unclear.
- Study design
- This is a Phase 1/2, open-label study, meaning you and your doctors will know what treatment you are receiving. It plans to enroll 32 participants to find the right dose of VNX-101.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to five years after receiving the treatment to monitor for side effects.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
At a glance
Conditions
Where it's being run
11 sites across 10 statesStudy leadership
- Vironexis Clinical Trials · STUDY_DIRECTOR · Vironexis Biotherapeutics Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Treatment emergent adverse events (TEAEs) and treatment-emergent serious events (TESAEs)Change from Baseline to Year 5 post dosing